Signaling pathways of inflammation in CIA model of rheumatoid arthritis regulated by cannabichromene
Michaela Sklenárová, Monika Šteigerová, Petr Jelínek, Mykhaylo Bazyuk, Sara Merdita, Baraa Chaban, Jan Hlaváč, Daniel Stránský, Markéta Fučíková, Miroslav Šoóš, Martin Šíma, Ondřej Slanař · 2026
Read Signaling pathways of inflammation in CIA model of rheumatoid arthritis regulated by cannabichromene by Michaela Sklenárová, Monika Šteigerová, Petr Jelínek, Mykhaylo Bazyuk, Sara Merdita, Baraa Chaban, Jan Hlaváč, Daniel Stránský, Markéta Fučíková, Miroslav Šoóš, Martin Šíma, Ondřej Slanař (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13555878.txt.
Description
Michaela Sklenárová leads an twelve-author team testing a cannabis compound against rheumatoid arthritis in cells and rats in a 2026 study. The compound, cannabichromene, does not cause a high and may calm inflammation. In vessel cells stirred by a bacterial toxin, it lowered a key inflammatory signal at low doses. Rats with induced joint disease then received the compound, a steroid, or salt water.
Treated rats scored better on arthritis measures and lost less weight, though paw swelling barely budged. Tissue tests showed a whole inflammatory chain turned down, from signal proteins to helper cell drivers. Parts of the cell's alarm assembly were also suppressed. Joint damage markers, though, did not move, so the authors call for more work.
Catalog record
| CREATOR | Michaela Sklenárová, Monika Šteigerová, Petr Jelínek, Mykhaylo Bazyuk, Sara Merdita, Baraa Chaban, Jan Hlaváč, Daniel Stránský, Markéta Fučíková, Miroslav Šoóš, Martin Šíma, Ondřej Slanař |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39244 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |